Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity
Therapy-related myelodysplasia and acute myeloma leukemia. Cytogenetic charaeteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen Series
Pederson-Gjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, Specht L and Osterlind K: Therapy-related myelodysplasia and acute myeloma leukemia. Cytogenetic charaeteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in The Copenhagen Series. Leukemia 7: 1975-1986, 1993.
Key enzymes of IMP metabolism: Transformation- And proliferation-linked alterations in gene expression
Weber G, Prajda N, Jackson RC. Key enzymes of IMP metabolism: transformation- and proliferation-linked alterations in gene expression. Advan Enzyme Regul 14: 3-24, 1976.
Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion
Raghavan D, Bishop J, Sampson D, et al: Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion. Cancer Chemother Pharmacol 16: 160-164, 1986.
Phase I clinical study with pharmacokinetic analysis of 2-β-D-ribofuranosyithiazole-4-carboxamide (NSC 286193) administered as a five day infusion
Trump DL, Tutsch RD, Koeller JN, Tormey DC. Phase I clinical study with pharmacokinetic analysis of 2-β-D-ribofuranosyithiazole-4-carboxamide (NSC 286193) administered as a five day infusion. Cancer Res 45: 2853-2858, 1985.
Phase I trial of tiazofurin administered by iv bolus daily for 5 days, with pharmacokinetic evaluation
Roberts JD, Stewart JA, McCormack JJ, et al. Phase I trial of tiazofurin administered by iv bolus daily for 5 days, with pharmacokinetic evaluation. Cancer Treat Rep 71: 141-149, 1987.
Phase I evaluation of pharmacokinetics of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide. NSC 286193)
Melink TJ, Von Hoff DD, Kuhn JG, et al: Phase I evaluation of pharmacokinetics of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide. NSC 286193). Cancer Res 45: 2859-2865, 1985.